183 results about "Allopurinol" patented technology

The present invention provides a method of predicting the risk of a patient for developing adverse drug reactions, particularly SJS or TEN. It was discovered that an HLA-B allele, HLA-B* 1502, is associated with SJS / TEN that is induced by a variety of drugs. The correlation with HLA-B* 1502 is most significant for carbamazepine-induced SJS / TEN, wherein all the patients tested have the HLA-B* 1502 allele. In addition, another HLA-B allele, HLA-B*5801, is particularly associated with SJS / TEN induced by allopurinol. Milder cutaneous reactions, such as maculopapular rash, erythema multiforme (EM), urticaria, and fixed drug eruption, are particularly associated with a third allele, HLA-B *4601. For any of the alleles, genetic markers (e.g., HLA markers, microsatellite, or single nucleotide polymorphism markers) located between DRB1 and HLA-A region of the specific HLA-B haplotype can also be used for the test.

The invention belongs to the field of pharmacogenomics and genetic diagnosis, and relates to a method used for detecting HLA-B*5801 alleles. The method comprises following steps: a DNA sample to be detected is taken, three pairs of specific primers and a pair of internal primers are taken, amplification of DNA segments is realized by using sequence specific primer method, and then the results of the amplification are analyzed by agarose gel electrophoresis; or sample DNA is extracted, a pair of specific primers, a pair of internal primers and three fluorescence probes are taken, amplification of DNA segments is realized by Taqman probe method using a fluorescence ration PCR instrument, and then the amplification curve is analyzed so as to obtain results. Results analysis methods such as agarose gel electrophoresis, high resolution melting curve and SYBRGreen fluorogenic quantitative PCR are employed in the method. The method has advantages of speediness, convenience, flexibility, high resolution and no contamination; is suitable for detection of HLA-B*5801 alleles in samples such as peripheral blood and hair; and can be used for determining the probability of severe skin adverse reaction of patients with gout or hyperuricemia caused by taking of allopurinol.

The present invention relates to a novel purpose of mangiferin compound for preventing and remedying hyperuricemia and gout. A study shows that the mangiferin compound has very strong anti-gout effect; 0.002mmol / kg (0.78mg / kg) of the dosage can reduce the serum uric acid level of a mouse with the hyperuricemia obviously; the mangiferin compound has higher activity than allopurinol and has little toxic and side effect; the maximum gastric infusion tolerance dose of the mouse is 47.4mmol / kg (20g / kg), which is lower than that of current clinical applied anti-gout medicines, such as colchicines, the allopurinol, sulphinpyrazone, etc.; the present invention can be applied to prepare for oral anti-gout medicines and health care products.

Disclosed is a pharmaceutical composition comprising tranilast or a pharmaceutically acceptable salt thereof and allopurinol or a pharmaceutically acceptable salt thereof, wherein the amount by weight of said allopurinol or pharmaceutically acceptable salt thereof in said composition is greater than the amount by weight of said tranilast or pharmaceutically acceptable salt thereof in said composition.

The invention discloses a synthesis method of allopurinol, which comprises the following steps of: 1) condensation reaction; 2) ring salt synthesis reaction; 3) treatment at a crude product section; and 4) treatment at a refining section. The synthesis method provided by the invention has the advantages that the process is simple, the product yield and quality can be effectively improved through the process provided by the invention, the energy consumption and the environmental pollution are reduced during reaction and purified water is used for refining the allopurinol.

The invention relates to a cartilage preservation solution. Each 1000ml of the preservation solution comprises 20-30mmol of potassium dihydrogen phosphate, 80mmol of histidine or 15mmol of a histidine salt, 75-95mmol of lactobionic acid, 50-70mmol of sucrose, 0.8-1.2mmol of allopurinol, 45-55g of low molecular dextran-40, 45-55mmol of NaCl, 25-35mmol of KCl, 3-7mmol magnesium sulfate, 70-90U of penicillin, 2-4mmol of reduced glutathione, 3-7mmol of adenosine, 2-5g of trehalose, and the balance deionized water, and the pH value of the cartilage preservation solution is 7.33-7.53. The cartilagepreservation solution is packaged, sealed and preserved at 0-4DEG C. By adopting the preservation solution to preserve cartilage tissues, the death speed of cartilage cells is slowed, the activity ofcartilage fibers is maintained, the performance of the cartilage tissues is kept, and the antibiotic property is increased, so the preservation solution has a good preservation effect and a long preservation time on the cartilage tissues, and is in favor of clinic cartilage tissue transplant operations.

The present invention relates to medicine form, and is especially slowly releasing allopurinol tablet and its preparation process. The slowly releasing allopurinol tablet includes allopurinol as main medicine component 10-70 wt%, slowly releasing skeleton matrix 1-15 wt%, soluble diluent 25-85 wt% and adhesive 1-10 wt%. The slowly releasing allopurinol tablet needs to be taken once a day and provides the patient with certain dependence to maintain smooth blood medicine concentration.

The invention provides a method for screening a xanthine oxidase inhibitor by ultra performance liquid chromatography and mass spectrometry. The method is used for analyzing the in-vitro inhibition rate of the extract or monomer of a natural product on the xanthine oxidase and the catalytic activity of the xanthine oxidase. By using the ultra performance liquid chromatography-mass spectrometry in the xanthine oxidase inhibitor screening, the method is rapid and accurate in sample detection, and the correlation coefficients of the linear equation reaches 0.998. The mass spectrometry has high accuracy and good specificity in detecting the mass electron ratio of a compound, and can be used for screening the xanthine oxidase inhibitor and for the kinetic study of the xanthine oxidase inhibitor without false positive and false negative results which occur in the spectrometry. The results showed that the inhibition rate I of 20 mumol / L allopurinol is 80%; the inhibition rate of 20 mumol / L isorhamnetin is 73%; the inhibition rate of 20 mumol / L genistein is 50%; and the inhibition rate of 0.1 mg / mL aqueous extract of Ginkgo biloba is 27%.

The present invention relates to one kind of organ preserving fluid and its preparation process. Each 1000 ml of the organ preserving fluid contains 5 mol / L concentration NaOH solution 3 ml, hydroxyethyl starch 58.5-71.5 g, potassium lactobionate 37.08-45.32 g, MgSO4.7H2O 1.12-1.38 g, adenosine 1.61-1.97 g, allopurinol 0.13-0.16 g, KH2PO4 3.15-3.85 g, cane sugar 9.23-11.29 g, glutathione 0.92-1.12 g, diltiazem hydrochloride 20 mg, KOH and double distilled water in proper amount. The organ preserving fluid has pH 7.3-7.5. Its preparation process includes setting double distilled water in 800 ml in some container, adding the said components via stirring, regulating pH with KOH, adding double distilled water to 1000 ml, filtering and abacterial preservation at 0-8 deg.c.

The invention relates to placenta preserving fluid with pH value of 7.33-7.83; the placenta preserving fluid per 1,000ml contains 10-15mmol of potassium dihydrogen phosphate, 30-40mmol of sodium chloride, 40-50mmol of potassium chloride, 8-10mmol of magnesium sulfate, 70-100mmol of histidine, 1.5-2.0mmol of allopurinol, 3mmol of reduced glutathione, 1-8ml of 2-mercaptoethanol, 8-10mmol of adenosine, 1,000,00-1,000,000U of penicillin, 60-100mg of streptomycin and 50-70mg of gentamicin. The placenta preserving fluid can store the delivered placenta for a long time, prevent from reduction of cell activity and control the bacteria contamination rate of the placenta to be in a low level.

The invention discloses application of cannabinoids in the preparation of a medicine for treating gout. The inventor found for the first time that cannabinoids have a very strong antigout effect, can significantly reduce serum urate level of hyperuricemia mice but have no remarkable influence on serum urate level of normal mice, can substantially inhibit toe swelling induced by sodium urate, have more excellent activity than allopurinol and have little toxic and side effect. The invention also provides a gout-treating medicinal preparation of the cannabinoids and a corresponding dosage form. By a conventional preparation method, various different dosage forms of medicines used in clinic can be prepared and are convenient to use.

The invention relates to the technical field of medicine, in particular to an allopurinol sustained-release pellet, and a preparation method and a preparation thereof. The allopurinol sustained-release pellet comprises the following components in parts by weight: 30-95 parts of allopurinol and 1-20 parts of anionic polymer, and further comprises a diluent or a pellet core. According to the allopurinol sustained-release pellet, the anionic polymer serves as both an adhesive and a sustained release material, and no additional adhesive is needed, so that the types and consumption of auxiliary materials are reduced, and the relative content of allopurinol in the pellet is improved. In addition, as the anionic polymer is applied in the pellet skeleton, the step of coating the sustained-release material is omitted, and accordingly, the preparation steps are reduced. Therefore, the allopurinol sustained-release pellet simplified not only the formula but also the preparation technology.

The invention relates to a detection method of HLA (Human Leukocyte Antigen)-B*58:01 allele. The detection method comprises the following steps: providing a mixture of a sample to be tested, a nucleic acid amplification system and a fluorescence detection system; circularly amplifying target polynucleotide through an amplified reaction; indirectly combining a fluorescence generating group and an amplified target polynucleotide sequence; and detecting the fluorescent amount generated by the fluorescence generating group so as to determine existence of the target polynucleotide and the relative amount thereof. The invention further discloses a kit for detecting the allele. The kit comprises a plurality of sealed centrifuge tubes which are respectively filled with a reaction liquid 1, a reaction liquid 2, a reaction liquid 3, an EZ Taq enzyme mixed liquid, a standard liquid 1 and a standard liquid 2 as well as the kit which separates and packages the centrifuge tubes in a centralized manner. The kit and the detection method provided by the invention are simple and convenient to operate, short in time consumed, strong in specificity and high in sensitivity. The kit and the detection device can be widely applied to detecting the HLA-B*58:01 allele and clinically avoiding severe untoward effects of skins of the HLA-B*58:01 allele patients caused by using allopurinol.

Evidence is presented that inflammation and injury involves activation of xanthine oxidoreductase (XOR) in the newly recruited mononuclear phagocytes (MNP). XOR has been shown to be increased predominantly in the MNP that increase rapidly in the lungs of rats that develop acute lung injury (ALI) following intratracheal cytokine insufflation. XOR was recovered from the MNP largely converted to its oxygen radical generating, reversible O-form, and alveolar MNP exhibited increased oxidative stress as evidenced by increased nitrotyrosine staining. Cytokine insufflation also increased alveolar cell apoptosis. A functional role for XOR in cytokine induced inflammation was demonstrated. Tungsten and allopurinol decreased MNP XOR induction, nitrotyrosine staining, inflammatory cell infiltration, and alveolar cell apoptosis. Transfer of control or allopurinol treated MNP into rat lungs and confirmed a specific role for MNP XOR in promoting lung inflammation. These data indicate that XOR can contribute to lung inflammation by its expression and conversion in a highly mobile inflammatory cell population.

The dispersive allopurinol and benzbromarone tablet has allopurinol and benzbromarone in the ratio of 5, and can disintegrate completely in 100 ml water at 20 deg.c within 3 min and through No. 2 sieve. It has the functions of treating various kinds of hyperuricemia and its clinical complications, especially gout with symptom, as well as various diseases resulting in raised uric acid in blood.

The invention provides an allopurinol derivative as shown in Formula I, and a preparation method and application thereof. Tumor growth can be effectively suppressed by the allopurinol derivative provided by the invention, the activity of the allopurinol derivative is equivalent to that of 17-AGG (17-allylamide-17-demethoxygeldanamycin) to which phase III clinical trial is performed, and the allopurinol derivative has a good antitumor effect. The activity of xanthine oxidase can be effectively suppressed by the allopurinol derivative, and the allopurinol derivative can be used for treating gout and provides a new drug choice for clinically treating cancer and gout. Additionally, the preparation method of the compound provided by the invention has the advantages of simplicity, lower cost, high yield and good industrial application prospect.

The invention discloses a composition with rhizoma alpiniae officinarum extract, flos chrysanthemi extract and a uric acid reducing function and application of the composition. The composition is a compound of the rhizoma alpiniae officinarum extract and the flos chrysanthemi extract. The rhizoma alpiniae officinarum extract is made of dry rhizoma alpiniae officinarum and is prepared by the aid ofultrasonic auxiliary ethanol extraction methods and macroporous resin separation and enrichment methods, and diphenylheptane and flavone compounds in the rhizoma alpiniae officinarum are pertinentlyextracted; the flos chrysanthemi extract is made of dry Bo flos chrysanthemi, Qi flos chrysanthemi and Jinsihuang flos chrysanthemi and is prepared by the aid of ethanol reflux extraction methods, andflavone substances in the flos chrysanthemi are pertinently extracted. The composition and the application have the advantages that the composition contains the abundant diphenylheptane compounds (more than 30%) and the abundant flavone (more than 7%) compounds, and is obvious in uric acid reducing activity (the in-vitro xanthine oxidase inhibitory activity is higher than 75 micro-mol of allopurinol equivalent weight / g); the composition has excellent flavor, is safe and reliable and can be applied to hyperuricemia prevention and adjuvant therapy healthcare foods or medicines, and raw materials for the composition are easily available.

The invention discloses a compound with an effect of treating and preventing hyperuricemia or gout and a preparation method as well as application thereof. The general structural formula of the compound is shown as a formula (I); the proportion of lesinuard and an allopurinol medicament can be effectively controlled by the series of the compounds, the dose and frequency are reduced, the effect of combination medication can be achieved by single-time medication, meanwhile the preparation process can be simplified, and the production cost is saved; since a linking group exists between the two compounds, the compound can only be hydrolyzed into two medicaments under the action of an enzyme for a certain time after the compound is orally taken and absorbed; thus, the half-life in vivo of the compound is increased by the process, namely the medicament achieve a slow release effect through a chemical coupling method.

The invention discloses application of high mangiferin and aglycon thereof in preparation of a medicament for preventing and treating hyperuricemia and in particular relates to application of high mangiferin and aglycon thereof in preparation of a medicament for preventing and treating hyperuricemia as well as gout and lithangiuria brought by the hyperuricemia, and a medicine application way. The high mangiferin and aglycon thereof provided by the invention can be used for obviously reducing the concentration of serum uric acid in an animal for experiment and have the serum uric acid inhibition effect similar to that of a xanthine oxidase inhibition medicament allopurinol; and simultaneously, the high mangiferin and aglycon thereof provided by the invention can be used for obviously improving the concentration of uric acid in urine and have the uric acid excretion promoting function similar to that of a uric acid excretion promoting medicament probenecid. The high mangiferin and aglycon thereof provided by the invention are efficient, low in toxicity and high in safety, thus the high mangiferin and aglycon thereof are wide in application prospect.

The invention discloses a biomarker for forecasting severe drug-induced cutaneous adverse reaction of a child patient and an application. The biomarker is capable of forecasting the risk of severe cutaneous adverse reaction of the child patient using beta-lactam antibiotics such as penicillin, cephalosporin, carbamazepine, lamotrigine, oxcarbazepine, phenytoin, allopurinol, nevirapine, abacavir, methazolamide and dapsone.

The invention discloses a traditional Chinese medicine composite with a function of inhibiting alpha-glucuroide and xanthine oxidase and a preparation method and applications thereof. The bulk pharmaceutical chemical of the traditional Chinese medicine composite comprises drynaria rhizome, and also can comprise tuber fleeceflower stem, wherein, the weight ratio of drynaria rhizome to tuber fleeceflower stem is (0.5-2): 1, the preferential weight ratio is 1:1. The traditional Chinese medicine composite is based on two enzyme inhibitors of alpha-glucuroide and xanthine oxidase, and has double functions of reducing postprandial plasma glucose and blood uric acid. The invention has rich resource and low price, is safe and non-toxic, and has consistent function with Glucobay and allopurinol, thus the invention can be used for treating the diseases of glucose tolerance defect, diabetes, obesity, hyperuricemia and gout and the like.

The present invention provides a method of predicting the risk of a patient for developing adverse drug reactions, particularly SJS or TEN. It was discovered that an HLA-B allele, HLA-B* 1502, is associated with SJS / TEN that is induced by a variety of drugs. The correlation with HLA-B* 1502 is most significant for carbamazepine-induced SJS / TEN, wherein all the patients tested have the HLA-B* 1502 allele. In addition, another HLA-B allele, HLA-B*5801, is particularly associated with SJS / TEN induced by allopurinol. Milder cutaneous reactions, such as maculopapular rash, erythema multiforme (EM), urticaria, and fixed drug eruption, are particularly associated with a third allele, HLA-B *4601. For any of the alleles, genetic markers (e.g., HLA markers, microsatellite, or single nucleotide polymorphism markers) located between DRB 1 and HLA-A region of the specific HLA-B haplotype can also be used for the test.

The invention discloses B cell epitope for xanthine oxidase and an antigen peptide containing the epitope. The antigen peptide is prepared by the following steps: B cell epitope for xanthine oxidase is connected to a linear B cell epitope FEYQD which is at a membrane-proximal region of insulinoma-associated protein-2 by a flexible peptide in a series connection, and a terminal is connected to a N terminal of Th2 auxiliary epitope P2 of P277 by a flexible peptide in a series connection. Serum which is obtained by immunization of mice with the antigen peptide is detected by Western blot, results show that an antibody which is specifically combined with xanthine oxidase is generated, and the antigen peptide is used for detecting xanthine oxidase; serum of the mice which are immunized by the antigen peptide can be used for inhibiting exogenous activity of xanthine oxidase, the difference between the inhibition rate of xanthine oxidase and the inhibition rate of allopurinol is not substantial (P>0.5), and the serum can be used for preparing xanthine oxidase inhibitor; the antigen peptide is used for treating gout, hepatopathy, nephrosis, atherosclerotic, diabetes, senile dementia, eye diseases, cardiovascular diseases, and other diseases due to xanthine oxidase abnormity, uric acid abnormity and oxidative stress disorder with important theoretical values and wide application prospects.

The invention discloses a liver preservation solution which contains the following components in per 100ml: 7-8g of 1,6-fructose diphosptate, 1-2g of glutathione, 2-3g of allopurinol, 0.3-0.5g of traditional Chinese medicine ligustrazine, 8-12mg of traditional Chinese medicine anisodamine and the balance of Ringer's solution added to 100ml. Proved by a large number of experiments, the liver preservation solution has a statistical meaning compared with an experiment contrast group, and two treatment groups (a group of the invention and an American UW treatment group) do not have the statistical meaning. The invention provides an excellent guarantee for long-acting liver preservation, has simple prescription and saves production and inspection cost for production and clinical application.

The invention relates to an allopurinol sustained release pellet, which does not need to adopt special equipment, and comprises allopurinol, sustained release material and hydrophobicbase with the mass ratio of 1%-50%. The hydrophobicbase can adjust the drug release, concretely, after the sustained release pellet enters the body, the sustained release pellet is limited due to the entering of water, so the drug release is slowed down, and the function of retarding the drug release is played.

The invention discloses an umbilical cord preservation fluid and an umbilical cord preservation method. The umbilical cord preservation fluid is prepared from 15-20 mmol of hyperbranched polyglycerol,99-101 mmol of lacturonic acid, 24-26 mmol of monopotassium phosphate, 4-6 mmol of magnesium sulfate, 4-6 mmol of adenosine, 2-4 mmol of glutathione reduction type, 6-10 mg of dexamethasone, 0.5-1.5mmol of allopurinol, 50-70 mmol of sucrose, 40-60 g of dextran, 18-22 mg of verapamil, 4-6 ml of sodium hydroxide and 19-21 ml of potassium hydroxide. When an umbilical cord is preserved , the cleanedumbilical cord is cut into small sections with the length of 3-5 cm, then immersed into a preservation liquid and preserved in an environment with the temperature of 3-5 DEG C. By adopting the preservation liquid, the problem that the umbilical cord cannot be preserved for a long time after being isolated can be effectively solved.

Disclosed are pharmaceutical compositions comprising, bucillamine, including bucillamine and allopurinol or colchicine, or pharmaceutically acceptable salts or solvates thereof, together with one or more pharmaceutically acceptable carriers, diluents and excipients. Methods for use of the said compositions in the treatment of gout and metabolic syndrome are also disclosed.

The invention provides cartilage preserving fluid and a utilization method thereof. The cartilage preserving fluid is prepared from monopotassium phosphate, histidine or histidine salt, lactobionic acid, saccharose, allopurinol, low-molecular dextran-40, NaCl, KCl, magnesium sulfate, penicillin, reduced glutathione, adenosine, trehalose, catechin, vitamin E and chondroitin sulfate, deionized waterserves as a solvent, a pH value is 7.35-7.52, and the cartilage preserving fluid is used for cartilage preservation at a temperature of 0-4 DEG C. The cartilage preserving fluid and the utilization method thereof have advantages that bioactivity of articular cartilage cells can be kept, degenerative changes of articular cartilages can be delayed, and assistances are provided for clinical treatment of large-area articular cartilage defects and cartilage tissue transplantation.

The invention relates to the field of medicines, and particularly discloses application of 5,6,7,4'-tetrahydroxy flavone and derivatives thereof in preparation of drugs for preventing and treating hyperuricemia and gout. The invention also provides capsules and sustained-release tablets for preventing and treating hyperuricemia and gout. The invention discovers that 5,6,7,4'-tetrahydroxy flavone and derivatives thereof have strong anti-gout action, can significantly reduce the serum uric acid level of mouse suffering from hyperuricemia at low dosage, have activity equivalent to that of allopurinol, have low toxic and side effects, have safety higher than that of anti-gout drugs such as colchicine, allopurinol and anturan used clinically at present, can be used for preparing drugs for preventing and treating hyperuricemia and gout, and have broad clinical application prospects.

The invention provides a purification method of allopurinol. The method provided by the invention comprises the following steps: 1) dissolving an allopurinol crude product in a high-boiling point polar organic solvent at the temperature of 100-190 DEG C; 2) performing decolorization treatment on a solution obtained in the step 1), and filtering when the solution is hot; 3) cooling and devitrifying filtrate obtained in the step 2), and separating to obtain purified allopurinol crystals. By adopting the method provided by the invention, the yield of the obtained allopurinol finished product is high, which can be as high as 90%, and the purity is good, which can be above 99.88%. Furthermore, the method provided by the invention has a simple process, the yield is greatly improved, the solvent can be completely recycled, environmental pollution is reduced, and the method is suitable for industrial production.